ONECUT2 As a Key Mediator of Androgen Receptor-independent Cell Growth and Neuroendocrine Differentiation in Castration-resistant Prostate Cancer

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582526

Authors

WonSeok William Choi

Julia L Boland

Jianqing Lin

Affiliations

Soon will be listed here.

Abstract

Despite androgen dependence in a majority of castration-resistant prostate cancers, some cancer cells are independent of androgen receptor (AR) function, a feature of heterogeneity in prostate cancer. One of the aggressive variants of prostate cancer that are AR independent is neuroendocrine prostate cancer (NEPC). This manuscript will focus on the new finding of human one cut domain family member 2 (ONECUT2) transcription factor and its role in castration resistance, especially in NEPC.

Citing Articles

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer.

Sreekumar A, Saini S Front Cell Dev Biol. 2023; 11:1075707.

PMID: 36711033 PMC: 9879360. DOI: 10.3389/fcell.2023.1075707.

Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.

Asberry A, Liu S, Nam H, Deng X, Wan J, Hu C Comput Struct Biotechnol J. 2022; 20:5873-5885.

PMID: 36382181 PMC: 9636493. DOI: 10.1016/j.csbj.2022.10.031.

New insights for drug resistance in metastatic castration-resistant prostate cancer.

Kushwaha P, Gupta S Cancer Drug Resist. 2022; 5(3):846-849.

PMID: 36176749 PMC: 9511793. DOI: 10.20517/cdr.2022.83.

References

Zhang J, Cheng J, Zeng Z, Wang Y, Li X, Xie Q . Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget. 2015; 6(39):42040-52. PMC: 4747208. DOI: 10.18632/oncotarget.5969. View

Jacquemin P, Lannoy V, Rousseau G, Lemaigre F . OC-2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor-6. J Biol Chem. 1999; 274(5):2665-71. DOI: 10.1074/jbc.274.5.2665. View

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z . Correction to: miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. 2021; 476(8):3215-3216. PMC: 8496573. DOI: 10.1007/s11010-021-04185-3. View

Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kim S . The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015; 12(6):922-36. DOI: 10.1016/j.celrep.2015.07.012. View

Guo H, Ci X, Ahmed M, Hua J, Soares F, Lin D . ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019; 10(1):278. PMC: 6336817. DOI: 10.1038/s41467-018-08133-6. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Ma Q, Wu K, Li H, Li H, Zhu Y, Hu G . ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression. Sci Rep. 2019; 9(1):20021. PMC: 6934839. DOI: 10.1038/s41598-019-56277-2. View

Aggarwal R, Zhang T, Small E, Armstrong A . Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014; 12(5):719-26. DOI: 10.6004/jnccn.2014.0073. View

10.

Meng F, Evans J, Bhupathi D, Banica M, Lan L, Lorente G . Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2011; 11(3):740-51. DOI: 10.1158/1535-7163.MCT-11-0634. View

11.

Lapuk A, Wu C, Wyatt A, McPherson A, McConeghy B, Brahmbhatt S . From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012; 227(3):286-97. PMC: 3659819. DOI: 10.1002/path.4047. View

12.

Lu T, Wu B, Yu Y, Zhu W, Zhang S, Zhang Y . Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis. Cancer Sci. 2018; 109(7):2221-2234. PMC: 6029829. DOI: 10.1111/cas.13633. View

13.

Rotinen M, You S, Yang J, Coetzee S, Reis-Sobreiro M, Huang W . ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018; 24(12):1887-1898. PMC: 6614557. DOI: 10.1038/s41591-018-0241-1. View

14.

Rickman D, Beltran H, Demichelis F, Rubin M . Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017; 23(6):1-10. DOI: 10.1038/nm.4341. View

15.

Kropp P, Gannon M . Onecut transcription factors in development and disease. Trends Dev Biol. 2016; 9:43-57. PMC: 5176019. View

16.

Chen J, Chen J, Sun B, Wu J, Du C . Accelerates Tumor Proliferation Through Activating Expression in Gastric Cancer. Cancer Manag Res. 2020; 12:6113-6121. PMC: 7398892. DOI: 10.2147/CMAR.S256316. View